Opioid Exposure Presents Risks to Pharmaceutical Industry

With opioid litigation pending in multiple jurisdictions, the risks facing companies across the pharmaceutical industry and related industries are growing.  Calvert has evaluated the risks facing such companies across this value chain and identified three key ESG exposures considered to be financially material for companies with exposure to opioids.  This brief discusses the key ESG factors on which Calvert evaluates companies with opioid exposure and responsible investment approach to opioid-exposed companies.

Stay Informed and Register at  mmi-sii.org    for ongoing updates and to participate in our private community.  A full copy of Calvert’s Opioid Exposure Presents Risks to Pharmaceutical Industry can be found here upon registration.